Resverlogix wraps early repurchase of all $6.73 million convertibles

By Jennifer Chiou

New York, Jan. 7 - Resverlogix Corp. announced that it completed the repurchase of all $6,728,000 of its convertible notes 2½ years prior to maturity.

On Nov. 18, the company's board authorized the repurchase of the convertibles due June 6, 2012.

The redemption price was $3.26, a 25% premium to the conversion price of $2.61.

Based in Calgary, Alta., Resverlogix is a biotechnology company focused on therapies for cardiovascular disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.